CELL INTELLIGENCE · 肿瘤细胞治疗研究

溶瘤病毒疗法在肿瘤微环境与 CAR 治疗交界处的作用：机制、临床转化与未来方向

Oncolytic virotherapy at the tumor microenvironment-CAR Therapy interface: Mechanisms, clinical translation, and future directions.

免疫肿瘤治疗药物的临床开发

Clinical development of immuno-oncology therapeutics.

晚期 HER2 阴性乳腺癌患者瘤内注射 talimogene laherparepvec（T-VEC）联合化疗或内分泌治疗的 Ib 期研究

Phase Ib study of intratumoral talimogene laherparepvec (T-VEC) in combination with chemotherapy or endocrine therapy in patients with advanced HER2-n

治疗黑色素瘤的当前及在研药物综述

A Review of Current and Pipeline Drugs for Treatment of Melanoma.

高级别胶质瘤的免疫治疗与靶向治疗：当前与未来方向

Immunotherapy and targeted therapy for high grade gliomas: current and future directions.

高级别胶质瘤是一种网络性疾病，涉及众多相互关联的分子和微环境现象，从肿瘤内在通路和抗原性到免疫识别与攻击，再到神经元对肿瘤和免疫信号的调控。新兴疗法通常同时利用其中若干交叉机制，为这些毁灭性癌症的未来临床治疗带来了希望。不适用。

黑色素瘤治疗进展：免疫治疗演变格局下 PD-1 抑制剂、T-VEC、mRNA 疫苗与 TIL（肿瘤浸润淋巴细胞）疗法综述

Advancements in Melanoma Treatment: A Review of PD-1 Inhibitors, T-VEC, mRNA Vaccines, and Tumor-Infiltrating Lymphocyte Therapy in an Evolving Landsc

用于治疗 PD-1/PD-L1 抑制剂耐药非小细胞肺癌 (NSCLC) 的新型免疫治疗药物

Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors.

黑色素瘤辅助治疗和新辅助治疗的研究进展

Advances in Adjuvant and Neoadjuvant Therapy for Melanoma.

叙述性综述：间变性淋巴瘤激酶 (ALK) 阳性肺癌的免疫治疗——现状与未来方向

Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer-current status and future directions.

源自当前及不断演进的 ALK+ 非小细胞肺癌肿瘤微环境认知的免疫调节策略，可能在 PD-1/PD-L1 免疫治疗之外对 ALK+ 非小细胞肺癌发挥作用。

超越检查点抑制：保持治疗选择开放

Beyond Checkpoint Inhibition: Keeping Therapeutic Options Open.